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Summary
Chronic liver disease due to alcohol use disorder contributes markedly to the global burden of 
disease and mortality1–3. Alcoholic hepatitis is a severe and life-threatening form of alcohol-
Duan et al. Page 2
Nature. Author manuscript; available in PMC 2020 May 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
associated liver disease. The gut microbiota promotes ethanol-induced liver disease in mice4, but 
little is known about microbial factors responsible for this process. We identified cytolysin, a two-
subunit exotoxin secreted by Enterococcus faecalis (E. faecalis)5,6, to cause hepatocyte death and 
liver injury. Compared with controls, patients with alcoholic hepatitis have increased fecal 
numbers of E. faecalis. The presence of cytolysin-positive (cytolytic) E. faecalis correlated with 
liver disease severity and mortality in patients with alcoholic hepatitis. Using humanized mice 
colonized with bacteria from feces of patients with alcoholic hepatitis, we investigated the 
therapeutic effects of bacteriophages that target cytolytic E. faecalis. We found these phages to 
decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our 
findings link cytolysin-positive E. faecalis with worse clinical outcomes and mortality in patients 
with alcoholic hepatitis. We show that bacteriophages can specifically target cytolytic E. faecalis, 
providing a method to precisely edit the intestinal microbiota. A prospective clinical trial with a 
larger cohort is required to validate human relevance of our findings and to test whether this new 
therapeutic approach is effective for patients with alcoholic hepatitis.
The most severe form of alcohol-related liver disease is alcoholic hepatitis; mortality ranges 
from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 days of a 
diagnosis of severe alcoholic hepatitis7−9. Therapy with corticosteroids is only marginally 
effective9. Early liver transplantation is the only curative therapy, but is offered only at select 
centers, to a limited group of patients10.
Alcohol-related liver disease can be transmitted via fecal microbiota4. We investigated 
microbes and microbial factors responsible for this transmissible phenotype and for 
progression of alcohol-related liver disease.
Cytolysin presence associates with increased mortality
To determine whether chronic alcohol use and alcoholic hepatitis are associated with an 
altered composition of the fecal microbiota, 16S ribosomal RNA (rRNA) gene sequencing 
was performed. Differences in fecal microbiota composition were noted in patients with 
alcohol use disorder and alcoholic hepatitis, compared to subjects without alcohol use 
disorder (controls) (Fig. 1a; Extended Data Fig. 1a–1b; Supplementary Tables 1 and 2). One 
significant difference we observed was an increase in the proportion of Enterococcus spp. In 
patients with alcoholic hepatitis, 5.59% of fecal bacteria were Enterococcus spp, compared 
with almost none in controls (0.023%; 0.004% of all reads in the Human Microbiome 
Project) or patients with alcohol use disorder (0.024%). Fecal samples from patients with 
alcoholic hepatitis had about 2,700-fold more Enterococcus faecalis (E. faecalis) than 
samples from controls, measured by quantitative PCR (qPCR) (Extended Data Fig. 1c), 
consistent with 16S rRNA sequencing results. About 80% of alcoholic hepatitis patients are 
E. faecalis positive in feces (Extended Data Fig. 1d).
Colonization of mice with E. faecalis induces mild hepatic steatosis and exacerbates ethanol-
induced liver disease11 by unclear mechanisms. Cytolysin is a bacterial exotoxin 
(bacteriocin) produced by E. faecalis12 that contains two post-translationally modified 
peptides, CylLL” and CylLS”, in its bioactive form6. The two peptides are encoded by two 
separate genes, cylLL and cylLS12. Cytolysin has lytic activity against not only Gram-
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positive bacteria but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA 
(cytolysin-positive) in fecal samples from 30% of patients with alcoholic hepatitis; none of 
the fecal samples from controls and only one sample from a patient with alcohol use 
disorder was cytolysin-positive, detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-
positive patients with alcoholic hepatitis died within 180 days after admission compared to 
only 3.8% of cytolysin-negative patients (P<0.0001) (Fig. 1c). Among those cytolysin-
positive patients, 72.2% died due to liver failure (including liver failure related 
complications such as gastrointestinal bleeding) (Supplementary Table 2). Infection was not 
associated with 30-day, 90-day or 180-day mortality (P=0.403, 0.234 or 0.098) in patients 
with alcoholic hepatitis.
Univariate logistic and Cox regression of laboratory and clinical parameters associated 
detection of cytolysin-encoding genes in feces with international normalized ratio (INR), 
platelet count, model for end-stage liver disease (MELD) score, sodium MELD (MELDNa) 
score, age, serum bilirubin, INR, and serum creatinine (ABIC) score, and death 
(Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-encoding 
genes in feces was still associated with 90-day (P=0.004) or 180-day mortality (P=0.001) 
(Supplementary Table 3), after we adjusted for the geographic origin of the patients; 
antibiotic treatment; platelet count; and creatinine, bilirubin, and INR as components of the 
MELD score. We found no serious multicollinearity between detection of fecal cytolysin 
and these cofactors (variance inflation factor (VIF) <1.6), indicating that cytolysin is an 
independent predictor of mortality in patients with alcoholic hepatitis. When we performed 
receiver operating characteristic (ROC) curve analysis for 90-day mortality, cytolysin had an 
AUC of 0.81, which was superior to other widely used predictors for mortality in clinical 
practice (Extended Data Fig. 1e). Based on our findings, we propose that the detection of 
cytolysin may be a prognostic factor for worse liver-related outcomes and death, and a 
stronger predictor of mortality than MELD, ABIC, and discriminant function (DF).
To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we performed 
targeted culturing from stool samples. Whole-genome sequencing of 93 E. faecalis isolates 
revealed broad phylogenetic diversity of cytolysin-positive E. faecalis from patients with 
alcoholic hepatitis (Fig. 1d), indicating that cytolysin production is a variable trait among E. 
faecalis isolates and that cytolysin is carried in mobile (genetic) elements, which include 
both chromosomally-encoded pathogenicity islands (PAI) and plasmids14. Detection of any 
other antimicrobial resistance genes or virulence genes in E. faecalis isolates did not 
correlate with disease severity or mortality in patients with alcoholic hepatitis 
(Supplementary Table 4).
The total amount of fecal E. faecalis or fecal E. faecalis positivity did not correlate with 
disease severity or mortality in patients with alcoholic hepatitis (Supplementary Tables 5 and 
6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis had similar 
amounts of fecal E. faecalis (Extended Data Fig. 1f). Although there were differences in the 
composition of the gut microbiota in patients with alcoholic hepatitis from different 
geographic regions (Extended Data Fig. 1g), the proportion of cytolysin-positive patients, 
total amount of fecal E. faecalis, fecal E. faecalis positivity (Extended Data Fig. 1h–1j), 
treatment, and clinical outcomes (30 day and 90 day mortality) did not differ significantly 
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among the regions/centers (Supplementary Table 7). In addition, cirrhosis was not associated 
with cytolysin-positivity, the total amount of fecal E. faecalis, or fecal E. faecalis positivity 
in alcoholic hepatitis patients (Extended Data Fig. 1k–1m; Supplementary Tables 4–6). 
These results confirm our findings that the presence of cytolysin producing E. faecalis, 
rather than the total amount or presence of E. faecalis, determines the severity of alcoholic 
hepatitis and mortality.
Cytolysin promotes ethanol-induced liver disease
To determine whether cytolysin contributes to liver damage mediated by E. faecalis, we 
gavaged mice with a cytolytic E. faecalis strain (FA2-2(pAM714)) or a non-cytolytic E. 
faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol 
diet15. Compared to mice given phosphate-buffered saline (PBS), mice fed ethanol after they 
were gavaged with cytolytic E. faecalis developed more severe liver injury, indicated by 
higher level of alanine amino-transferase (ALT) (Extended Data Fig. 2a) and increased 
hepatic steatosis (Extended Data Fig. 2b and 2c). Mice fed ethanol after they were gavaged 
with cytolytic E. faecalis also had more liver inflammation with higher expression levels of 
mRNAs encoding inflammatory cytokines and chemokines (Il1b, Cxcl1, and Cxcl2) 
(Extended Data Fig. 2d–2f) compared with mice given PBS. Mice fed ethanol after they 
were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced liver 
injury, steatosis, and inflammation (Extended Data Fig. 2a–2f) and longer survival times 
(Extended Data Fig. 2g), compared with mice fed ethanol after they were administered 
cytolytic E. faecalis.
To explore the mechanism of cytolysin-associated liver damage, we measured cytolysin in 
the liver. CylLS was significantly increased in livers of mice given cytolytic E. faecalis but 
not mice that were not given E. faecalis or mice gavaged with non-cytolytic E. faecalis 
following chronic ethanol administration (Extended Data Fig. 2h). E. faecalis was detectable 
in the liver of mice given cytolytic and non-cytolytic E. faecalis and fed an ethanol diet, but 
not when fed an isocaloric (control) diet (Extended Data Fig. 2i), indicating that ethanol-
induced changes in the gut barrier are necessary for translocation of cytolytic E. faecalis 
from the intestine to the liver. Livers of ethanol-fed mice given cytolytic and non-cytolytic E. 
faecalis had positive E. faecalis cultures (Extended Data Fig. 2j). We observed increased 
intestinal permeability in ethanol-fed mice compared with isocaloric diet-fed mice, but this 
was independent of gavaging cytolytic or non-cytolytic E. faecalis following chronic ethanol 
administration (Extended Data Fig. 2k), indicating that cytolysin does not affect intestinal 
barrier function.
Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly change 
the composition of the intestinal microbiota, based on 16S rRNA gene sequencing 
(Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic 
metabolism of ethanol, based on serum levels of ethanol and hepatic levels of Adh1 and 
Cyp2e1 mRNAs (encoding the two primary enzymes that metabolize ethanol in the liver) 
(Extended Data Fig. 2m and 2n). These results indicate that E. faecalis that produce 
cytolysin promote ethanol-induced liver disease in mice.
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To extend our findings to humans, we colonized germ-free mice with feces from cytolysin-
positive and -negative patients with alcoholic hepatitis (Supplementary Table 8). Consistent 
with our findings from mice colonized with cytolytic E. faecalis, gnotobiotic C57BL/6 mice 
colonized with feces from two different cytolysin-positive patients developed more severe 
ethanol-induced liver injury, steatosis, inflammation, and fibrosis than mice given feces from 
two different cytolysin-negative patients (Fig. 2a–2f; Extended Data Fig. 3a–3d). 
Transplantation of feces from cytolysin-positive patients reduced survival time of the mice 
(Extended Data Fig. 3e) and increased translocation of cytolytic E. faecalis to the liver 
following ethanol administration (Fig. 2g). Overall composition of the intestinal microbiota 
was not different between mice colonized with feces from cytolysin-positive or -negative 
alcoholic hepatitis donors following the control diet, based on 16S rRNA gene sequencing. 
Mice transplanted with feces from one cytolysin-positive alcoholic hepatitis patient (#2) 
showed a microbiota significantly different from the other mouse groups following ethanol 
administration (Extended Data Fig. 3f). Interestingly, non-cytolytic E. faecalis was not 
detected in stool samples from donors with cytolytic E. faecalis (Extended Data Fig. 3g). We 
did not observe differences in intestinal absorption or hepatic metabolism of ethanol 
between mice colonized with feces from cytolysin-positive vs cytolysin-negative patients 
(Extended Data Fig. 3h and 3i). Together, these results provide further evidence that 
cytolysin promotes ethanol-induced liver disease.
To determine the mechanism by which cytolysin increases liver disease, we isolated 
hepatocytes from mice on ethanol or control diets and stimulated them with pure bioactive 
cytolysin peptides (CylLL” and CylLS”)6. Incubation of the primary mouse hepatocytes with 
two cytolysin subunits caused a dose-dependent increase in cell death compared to 
hepatocytes incubated with vehicle or with one subunit alone (Fig. 2h). Interestingly, when 
we isolated hepatocytes from ethanol-fed mice and then incubated those hepatocytes with 
ethanol, we did not observe increased levels of cytolysin-induced cell death compared to 
hepatocytes isolated from mice on the control diet, indicating that cytolysin-induced 
hepatocyte cell death was independent of ethanol. The cytotoxic effects of cytolysin are 
likely mediated by pore formation, resulting in cell lysis14.
Bacteriophage treatment attenuates alcohol-related liver disease in mice
To further demonstrate the potential causative role of cytolytic E. faecalis for the 
development of ethanol-induced steatohepatitis, we investigated the effects of treatment with 
bacteriophages. Bacteriophages (phages) are ubiquitous in bacteria-rich environment, 
including the gut16. E. faecalis phages that are highly-strain specific can be isolated17, 
potentially making direct editing of gut microbiota feasible. We have shown that Atp4aSl/Sl 
mice, which lack gastric acid, have overgrowth of intestinal enterococci, associated with 
increased susceptibility to alcohol-induced steatohepatitis11. Gavaging of wild-type mice 
with an E. faecalis strain isolated from Atp4aSl/Sl mice increased ethanol-induced 
steatohepatitis11. We found that this E. faecalis strain expressed cytolysin. We then isolated 
four distinct bacteriophages from sewage water. These bacteriophages lyse the cytolytic E. 
faecalis strain isolated from Atp4aSl/Sl mice. All four phages were podophages of the 
virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and their wild-type 
littermates were then placed on the chronic–binge ethanol diet and gavaged with the lytic 
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bacteriophage cocktail (Extended Data Fig. 5). Bacteriophages directed against Caulobacter 
crescentus (C. crescentus), a bacterium that is present in fresh water lakes and streams18, but 
does not colonize humans or rodents19,20, were used as controls. Compared to Atp4aSl/Sl 
mice gavaged with control bacteriophage or vehicle, Atp4aSl/Sl mice gavaged with 
bacteriophages that target cytolytic E. faecalis had less liver injury, steatosis, and 
inflammation following chronic ethanol feeding (Extended Data Fig. 5a–5f). Administration 
of E. faecalis bacteriophage significantly reduced levels of cytolysin in the liver (Extended 
Data Fig. 5g) and fecal amounts of Enterococcus (Extended Data Fig. 5h). Bacteriophage 
administration did not affect the overall composition of the fecal microbiome, intestinal 
absorption or hepatic metabolism of ethanol (Extended Data Fig. 5i–5k).
To develop a novel therapeutic approach to precisely edit the intestinal microbiota, cytolytic 
E. faecalis strains were cultured from fecal samples of patients with alcoholic hepatitis. We 
then isolated lytic bacteriophages from sewage water against these cytolytic E. faecalis 
strains and these phages had siphophage or myophage morphology (Fig. 3a; Extended Data 
Fig. 6). Gnotobiotic mice were colonized with feces from two different cytolysin-positive 
patients with alcoholic hepatitis (Supplementary Table 8) and given 3–4 different, but 
patient-specific lytic phages against cytolytic E. faecalis. The phages against cytolytic E. 
faecalis abolished ethanol-induced liver injury and steatosis, based on lower levels of ALT, 
percentage of TUNEL-positive hepatic cells, hepatic triglycerides and oil red O-staining 
(Fig. 3b–3d; Extended Data Fig. 7a–7b), decreased hepatic levels of Il1b, Cxcl1, Cxcl2, 
Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLs, compared with mice given 
control phages (against C. crescentus) (Fig. 3e–3h; Extended Data Fig. 7c–7d). Treatment 
with phages against cytolytic E. faecalis also reduced fecal amounts of Enterococcus 
(Extended Data Fig. 7e) without affecting the overall composition of the gut microbiota 
(Extended Data Fig. 7f). Intestinal absorption of ethanol and hepatic metabolism were 
similar in all groups (Extended Data Fig. 7g–7h).
To demonstrate that the effect of bacteriophage treatment occurs via targeting of cytolysin-
positive E. faecalis, rather than reduction in cytolysin-negative E. faecalis, we colonized 
gnotobiotic mice with feces from cytolysin-negative patients with alcoholic hepatitis 
(Supplementary Table 8). Bacteriophages against non-cytolytic E. faecalis from patients 
were isolated from sewage water, and they had siphophage or podophage morphology (Fig. 
4a; Extended Data Fig. 8). These phages did not reduce features of ethanol-induced liver 
disease compared with control phages (Fig. 4b–4g; Extended Data Fig. 9a–9h), despite the 
reduction of fecal Enterococcus (Fig. 4h). Our findings indicate that lytic bacteriophage 
treatment can selectively attenuate ethanol-induced liver disease caused by cytolysin-
positive E. faecalis in humanized mice.
Discussion
Phage-based therapies have been studied predominantly in patients with bacterial infections 
in the gastrointestinal tract21−23, urinary tract24,25 and other organ systems26−28. The results 
of these studies, while mixed in terms of efficacy, strongly suggest that phage treatment 
offers a safe alternative to antibiotics26,27. However, safety studies are required for complex 
populations such as patients with alcoholic hepatitis, since phages can induce a strong 
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immune reaction29. Future work is required to determine if bacteriophages that target 
cytolytic E. faecalis might be used to treat patients with alcoholic hepatitis, a life-threatening 
disease with no effective treatment. Our data also suggest that cytolysin may be used as a 
predictive biomarker of severe alcoholic hepatitis; So an independent, prospective cohort is 
now needed to validate cytolysin as a biomarker and to extend the bacteriophage findings to 
human patients.
Eradication of this specific bacterial strain might produce better outcomes than current 
treatments. Remarkably, environmental sources can be used to easily isolate phages that 
target cytolysin-positive E. faecalis. We provide the first example of the efficacy of phage-
based approaches in mice for a disease that is not considered a classic infectious disease. A 
clinical trial with a larger cohort is required to validate human relevance of our findings and 
to test this new therapeutic approach for patients with alcoholic hepatitis.
Methods
Patient cohorts
Patient cohorts have been described30−32. We evaluated 26 subjects without alcohol use 
disorder (controls; social drinkers consuming less than 20 g/day), 44 patients with alcohol 
use disorder, and 88 patients with alcoholic hepatitis. Patients with alcohol use disorder 
fulfilling the DSM IV criteria33 of alcohol dependence and with active alcohol consumption 
(self-reported > 60 g/day) presented with various stages of liver disease (21% had advanced 
F3/4 fibrosis based on fibrosis-4 index (FIB-4); Supplementary Table 1). Patients with 
alcohol use disorder were recruited from an alcohol withdrawal unit in San Diego, USA and 
Brussels, Belgium where they followed a detoxification and rehabilitation program. At 
admission to the hospital, a complete medication and medical history is taken, and a 
complete physical examination is performed, including collection of biospecimens, basic 
demographic data, such as age, gender, weight and height, and self-reported daily alcohol 
consumption. Patients were actively drinking until the day of admission. Controls or patients 
with alcohol use disorder did not take antibiotics or immunosuppressive medication during 
the two months preceding enrollment. Other exclusion criteria were diabetes, inflammatory 
bowel disease, known liver disease of any other etiology, and clinically significant cardio-
vascular, pulmonary or renal co-morbidities. Alcoholic hepatitis patients were enrolled from 
the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from centers 
in the USA, Mexico, United Kingdom, France and Spain. Inclusion criteria were active 
alcohol abuse (> 50 g/day for men and > 40 g/day for women) in the last 3 months, aspartate 
aminotransferase (AST) > alanine aminotransferase (ALT) and total bilirubin > 3 mg/dl in 
the past 3 months, liver biopsy and/or clinical picture consistent with alcoholic hepatitis. 
Exclusion criteria were autoimmune liver disease (ANA > 1/320), chronic viral hepatitis, 
hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic terminal disease, 
pregnancy, and lack of signed informed consent. In all patients, the clinical picture was 
consistent with alcoholic hepatitis and in patients who underwent liver biopsy, the histology 
was in line with the diagnosis of alcoholic hepatitis. Liver biopsies were only done if 
clinically indicated as part of routine clinical care for diagnostic purposes of alcoholic 
hepatitis. Biospecimens were collected during their admission to the hospital. The median 
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time of specimen collection was 4 days following admission to the hospital (range 0-24, 
n=82). For one patient who underwent liver transplantation, the transplantation date was 
considered as date of death. Patients were censored at the time point they were last seen 
alive. The baseline characteristics are shown in Supplementary Tables 1 and 2. Fecal 16S 
rRNA sequencing, Enterococcus culture and qPCR were performed. The MELD score, 
ABIC score and DF were calculated from all alcoholic hepatitis patients from whom 
respective laboratory values were available. The protocol was approved by the Ethics 
Committee of Hôpital Huriez (Lille, France), Universidad Autonoma de Nuevo Leon 
(Monterrey, México), Hospital Universitari Vall d'Hebron (Barcelona, Spain), King's College 
London (London, UK), Yale University (New Haven, USA), University of North Carolina at 
Chapel Hill (Chapel Hill, USA), Weill Cornell Medical College (New York, USA), 
Columbia University (New York, USA), University of Wisconsin (Madison, USA), VA San 
Diego Healthcare System (San Diego, USA), University of California San Diego (La Jolla, 
USA) and Université Catholique de Louvain (Brussels, Belgium). Patients were enrolled 
after written informed consent was obtained from each patient.
Mice
C57BL/6 mice were purchased from Charles River and used in Figure 2h and Extended Data 
Figure 2. C57BL/6 germ-free mice were bred at UCSD and used in Figure 2a-2g, Figure 3, 
Figure 4, Extended Data Figure 3, Extended Data Figure 7, and Extended Data Figure 9. 
Sublytic Atp4aSl/Sl mice on a C57BL/6 background have been described11,34 and 
heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate mice and their 
wild-type littermates were used in Extended Data Figure 5.
Female and male mice (age, 9–12 weeks) were placed on a chronic–binge ethanol diet 
(NIAAA model) as described15. Mice were fed with Lieber-DeCarli diet and the caloric 
intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study 
period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) in 
the early morning and sacrificed 9 hours later. Pair-fed control mice received a diet with an 
isocaloric substitution of dextrose.
Stool samples from patients with alcoholic hepatitis (see Figure 1) were used for fecal 
transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g 
stool dissolved in 30 ml Luria-Bertani (LB) medium containing 15% glycerol under 
anaerobic conditions), starting at an age of 5–6 weeks and repeated two weeks later. Two 
weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) diet.
In studies of the effects of cytolysin, 5 × 108 colony forming units (CFUs) of a cytolytic E. 
faecalis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2-2(pAM771))5 (E. 
faecalis Δcytolysin) (kindly provided by Dr. Michael S. Gilmore), or PBS (vehicle control) 
were fed to mice by gavage every third day, starting from day 6 through day 15 of ethanol 
feeding (see above). Administration every third day was necessary, given that E. faecalis 
does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of bacteriophage 
treatment, 1010 plaque forming units (PFUs) E. faecalis phages (or C. crescentus phage 
phiCbK as control)35 were gavaged to the mice one day before the ethanol binge (at day 16). 
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All animal studies were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of California, San Diego.
Bacteriophages isolation and amplification
E. faecalis strain from Atp4aSl/Sl mice feces was isolated before11 and was used to isolate 
phages Efmus1, Efmus2, Efmus3 and Efmus4. E. faecalis strains from human stool samples 
were isolated using methods described below and the corresponding phages were named as 
Ef with patient number plus a digit (Ef for E. faecalis, last digit for isolation order). All E. 
faecalis strains were grown statically in brain heart infusion (BHI) broth or on BHI agar at 
37°C. C. crescentus phage phiCbK was purified as previously described35.
E. faecalis phages were isolated from untreated raw sewage water obtained from North City 
Water Reclamation Plant in San Diego, California. Fifty milliliter raw sewage water was 
centrifuged at 8,000 x g for 1 min at room temperature (RT) to pellet large particles. The 
supernatant was passed through a 0.45 μm and then a 0.2 μm syringe filter (Whatman, PES 
membrane). One hundred microliter of the clarified sewage was mixed with 100 μl overnight 
E. faecalis culture and then added to BHI broth top agar (0.5% agar) and poured over a BHI 
plate (1.5% agar). After overnight growth at 37°C, the resulting plaques were recovered 
using a sterile pipette tip in 500 μl PBS. Phages were replaqued on E. faecalis three more 
times to ensure that the phages were clonal isolates.
High-titer phage stocks were propagated by infecting 200 ml of exponentially growing E. 
faecalis at a multiplicity of infection (MOI) of 0.1 in BHI broth containing 10 mM MgSO4. 
Lysis was allowed to proceed for up to six hours at 37°C with shaking. The lysates were 
centrifuged at 10,000 x g for 20min at RT to remove the remaining bacterial cells and debris. 
Supernatant was then vacuum filtered through a 0.2 μm membrane filter and kept at 4°C 
until use.
Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-X UF 
Concentrators with 100,000-molecular-weight-cutoff (MWCO) to a volume of 
approximately 1 ml. Following concentration, the culture medium was replaced with PBS 
via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml 
and adjusted to the required PFUs.
Whole-genome sequencing for bacteriophages
For all phages except Efmus4, 10 ml of lysates were treated with 10 μg/ml each of DNase 
and RNase at 37°C for 1 hour and phages were precipitated by adding 1M NaCl and 10% 
(w/v) polyethylene glycol 8000 (PEG 8000) and incubated at 4°C overnight. Precipitated 
phages were then pelleted by centrifugation at 10,000 x g for 10 min at 4°C and resuspended 
in 500 μl of resuspension buffer (5 mM MgSO4). Phage DNA was then extracted using 
Promega Wizard DNA Clean-up kit (Promega). Phage genomes were sequenced using a 
combination of Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. 
Illumina sequencing libraries were prepared using the Nextera XT library kit with bead-
based size selection prior to loading onto Illumina flow cells. Sequencing was performed 
with either Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 
2 × 150-bp paired-end formats. ONT MinION sequencing libraries were prepared using the 
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Rapid Barcoding Kit (SQK-RBK004) and loaded onto MinION R9.4 flow cells. ONT reads 
were basecalled with Albacore v2.3.4 (ONT). The sequence reads were demultiplexed and 
adapters trimmed from ONT reads using Porechop v0.2.336. A hybrid Illumina-ONT de 
novo assembly was performed using the Unicycler v0.4.7 pipeline37. Subsequently, Pilon 
v1.2238 was used iteratively to polish the assemblies with Illumina reads until no additional 
corrections could be made.
For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45 μm and 0.2 
μm filters (VWR) and purified on a cesium chloride (CsCl) density gradient39. One milliliter 
of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) and 
treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qiagen), 
amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using a 
Bioruptor (Diagenode). Libraries were created using the Ion Plus fragment library kit and 
sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life 
Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC 
Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using CLC 
Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read overlap39. 
Reads were assembled into a single contig of 18,186 bp (20,118 x coverage).
Mapping of ONT reads to the hybrid assemblies was used to determine the orientation and 
terminal ends of linear phage genomes while reference genomes served as guides to orient 
circular phage genomes. Phage genome assemblies were annotated using the NCBI 
Prokaryotic Genome Annotation Pipeline (PGAP)40,41.
Phage raw sequence reads and annotated genomes are available at NCBI under the following 
consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank accession 
numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 (MK721185), 
Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 (MK721192), Ef5.1 
(MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 (MK721191), Ef6.1 
(MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 (MK721190), Ef7.1 
(MK721194), Ef7.2 (MK721183), Ef7.3 (MK721184) and Ef7.4 (MK721198).
Genetic maps of bacteriophage genomes were generated by LinearDisplay.pl (https://
github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig (https://
sourceforge.net/projects/mcj/) to render high-quality images. Preliminary annotation of 
genes was derived from the automated annotation and from Phage_Finder42, which uses 
curated HMMs and databases of core phage gene to annotate core gene functions. 
Annotation was then manually reviewed to assign the final colors.
Bacteriophage phylogenetic tree
A phage whole genome phylogeny tree was generated from a pairwise distance matrix 
calculated with the MASH program, which approximates average nucleotide identity 
(ANI)43. First, a sketch file was created from all the 19 E. faecalis phage genomes isolated 
and sequenced in this study plus 54 Enterococcus phage genomes obtained from GenBank, 
with 5000 12mers generated per genome (mash sketch -k 12 -s 5000). The sketch file was 
then compared to all the initial phage genome sequences to generate the ANI matrix using 
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the mash distance command using default settings. The GGRaSP R-package was used to 
calculate the UPMGA phylogeny from the ANI distance matrix, after redundant phage 
genomes (genomes ANI > 99.985) were removed using the GGRaSP R-package with a user 
defined cutoff of 0.015 (ggrasp.cluster (threshold = 0.015)). The resulting dendrogram was 
translated into newick format using the APE R package44, loaded into the iTOL tree 
viewer45, and annotated with taxonomic information and manually-entered clade 
identification.
Electron microscopy
Bacteriophage morphology was examined by transmission electron microscopy of 
negatively stained grids, prepared using the valentine method46 with either 2% uranyl-
acetate or 2% phosphotungstic acid, and examined at an acceleration voltage of 100KV in 
the JEOL 1200 EX Transmission Electron Microscope.
Bacterial DNA extraction and 16S rRNA sequencing
DNA from human stool samples, mouse liver sections or bacterial culture was extracted as 
described before11, and DNA from mouse feces was extracted using QIAamp Fast DNA 
Stool kit (QIAGEN). 16S ribosomal RNA (rRNA) PCR was completed using Illumina 
adaptor and barcode ligated 16S primers targeting the V4 region of the 16S rRNA gene47,48. 
Amplicons were purified using the Qiaquick PCR purification kit (QIAGEN) using 
manufacturer’s specifications. Purified amplicons were then quantified via TECAN assay 
(Tecan, Switzerland), normalized, and pooled in preparation for 16S rRNA sequencing. 
Pooled library was quantified and checked for quality using Agilent 2100 Bioanalyzer 
(Agilent Technologies). Library was sequenced on Illumina MiSeq (Illumina) using V2 
reagent chemistry, 500 cycles, 2 x 250bp format using manufacturer’s specifications. 16S 
sequence reads were processed and OTUs were determined using our MOTHUR-based 16S 
rDNA analysis workflow as described previously11,49. Raw 16S sequence reads can be 
found in the NCBI SRA associated with Bioproject PRJNA525701.
Real-time quantitative PCR
Bacterial genomic DNA was extracted from human stool samples and mouse liver11. RNA 
was extracted from mouse liver and cDNAs were generated11. Primer sequences for mouse 
genes were obtained from the NIH qPrimerDepot. Primer sequences for E. faecalis 16S 
rRNA gene, E. faecalis cylLS and cylLL genes were described before50,51. All primers used 
in this study are listed in Supplementary Table 9. Mouse gene expression and amplification 
of bacterial genes were determined with Sybr Green (Bio-Rad Laboratories) using ABI 
StepOnePlus real-time PCR system. The qPCR value of mouse genes was normalized to 
18S.
E. faecalis isolation and whole-genome sequencing
To isolate E. faecalis strains from human subjects, 50–300 mg of human stool was 
resuspended in 500 μl PBS, serial dilutions were made, and 100 μl was placed on plates with 
selective medium, BBL Enterococcosel broth (Becton Dickinson). Enterococci colonies 
were identified by the production of dark brown or black color generated by hydrolysis of 
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esculin to esculetin that reacts with ferric ammonium citrate. Each Enterococcus colony was 
then picked, and qPCR was performed to identify E. faecalis, using specific primers against 
the E. faecalis 16S rRNA gene50. For each subject, 1 – 6 E. faecalis colonies were analyzed 
and bacterial genomic DNA was then extracted as described in above section.
DNA sequencing was performed on the Illumina HiSeq Ten X generating paired-end reads 
(2 x 151bp). Bacterial genomes were assembled and annotated using the pipeline described 
previously52. Antimicrobial resistance and virulence genes including cytolysin (cyl) genes 
carried by E. faecalis isolates were identified by comparing individual genome assemblies 
against the CARD and VFDB databases using abricate v0.8.10 (https://github.com/
tseemann/abricate), respectively53,54.
For the phylogeny of E. faecalis, the genome assemblies of the study isolates were annotated 
with Prokka55, and a pangenome estimated using Roary52. A 95% identity cut-off was used, 
and core genes were defined as those in 99% of isolates. A maximum likelihood tree of the 
SNPs in the core genes was created using RAxML56 and 100 bootstraps. The resulting tree 
was visualized using iTOL45. Genome sequence data of E. faecalis strains isolated in this 
study have been deposited in the European Nucleotide Archive (ENA) under the accession 
number PRJEB25007. Sequence reads are available at ENA under Run accession IDs 
ERR3200171-ERR3200263.
E. faecalis culture
All E. faecalis strains were grown statically in brain heart infusion (BHI) broth or on BHI 
agar plate at 37°C. 50 μg/ml erythromycin was added when cytolytic and non-cytolytic E. 
faecalis strains were grown (Extended Data Figure 2).
Fecal Enterococcus level determination
To determine fecal enterococci level in mice, 10–30 mg of mouse feces was resuspended 
into 500 μl PBS and serial dilutions were made. Five microliters of each dilution from each 
sample were spotted onto a plate with a selective medium, BBL Enterococcosel broth 
(Becton Dickinson) and the plates were then incubated at 37°C overnight. For Extended 
Data Fig. 2o, agar plates contained 50 μg/ml erythromycin. Enterococci colonies were 
identified by the production of dark brown or black color generated by hydrolysis of esculin 
to esculetin that reacts with ferric ammonium citrate. Colony numbers of each sample were 
then counted and CFUs were calculated.
Cytolysin expression and purification
To purify bioactive CylLL” and CylLS”, an E. coli heterologous expression system was used. 
Briefly, either Hisx6-CylLL or Hisx6-CylLS were co-expressed with CylM (enzyme that 
performs dehydration and cyclization reactions on cytolysin) in E. coli to yield fully 
dehydrated and cyclized full-length peptides. The His-tag and leader peptide were then 
removed using recombinant CylA (27-412), the soluble domain of the native peptidase used 
in cytolysin maturation, to yield bioactive CylLL” or CylLS”. The resulting core peptides 
were further purified by reversed-phase HPLC.
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The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 
backbone vector which contained the cylM gene in MCSII6. The cylA (27–412) gene was 
previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star™ 
(DE3) cells (50 μl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, 
cylLS_cylM:pRSFDuet or cylA (27-412):pRSFDuet plasmids via KCM chemical 
transformation. The cells were plated on LB agar plates supplemented with kanamycin (50 
μg/ml) and grown at 37°C overnight. One colony was picked to inoculate 15 ml of LB broth 
supplemented with kanamycin overnight at 37°C. The culture was used to inoculate 1.5 
liters of terrific broth supplemented with kanamycin. Cultures were grown with shaking at 
37°C to an OD600 of 0.8. The temperature of the incubator was lowered to 18°C and 
expression was induced with the addition of 0.3 mM final concentration of isopropyl β-D-
thiogalactoside. The cultures were allowed to incubate at 18°C for 18 hours. The cells were 
collected by centrifugation at 5000 x g for 12 min. The cell paste was collected and frozen at 
-70°C.
For the purification of the protease CylA (27–412), the cell paste was thawed and 
resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell suspension 
was lysed by homogenization. The lysate was clarified by centrifugation at 13,000 x g for 45 
min and filtered through a 0.45 μm centrifugal filter (Thermo Scientific). The clarified lysate 
was applied to a pre-equilibrated HisTrap HP 5 ml column (GE Healthcare) through a 
peristaltic pump. The loaded column was connected to an ÄKTA pure 25 M system. The 
protein was eluted by a linear gradient of LanP buffer to Elution Buffer (20 mM HEPES, 1 
M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. The purest fractions, as 
determined by 4%–20% SDS-PAGE, were combined, concentrated to 1 mg/ml by Amicon 
Ultra Centrifugal Filters (30 kDa MWCO), and buffer exchanged into storage buffer (20mM 
HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by PD-10 desalting column (GE Healthcare). 
Protein concentration was determined by absorbance at 280 nm.
For the purification of CylLL” and CylLS” peptides, the cell paste was thawed and 
resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM 
NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2 sec pulse 
on, 5 sec pulse off, 7 min total pulse on time). The cell lysate was clarified by centrifugation 
at 13,000 x g for 45 min. The clarified cell lysate was filtered through a 0.45 μm centrifugal 
filter and applied via gravity flow to a pre-equilibrated, 2 ml bed volume of His60 Ni 
Superflow Resin (Clonetech). After the lysate had been applied, the resin was washed with 
15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM 
imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash Buffer (20 mM 
NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the guanidine HCl. The 
peptides were eluted with 10 ml of LanA Elution Buffer (20 mM NaH2PO4, 500 mM NaCl, 
500 mM imidazole, pH 7.5). A 0.02 mg/ml final concentration of CylA (27–412) was added 
to the elution fraction and allowed to incubate at room temperature overnight to remove the 
leader peptide.
The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic acid. 
The solution was centrifuged at 4,500 x g for 10 min and filtered through a 0.45 μm syringe 
filter (Thermo Scientific). The core peptides were purified by semi-preparative reverse phase 
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HPLC using a Phenomenex Jupiter Proteo column (10 mm x 250 mm, 4 μm, 90 Å) 
connected to an Agilent 1260 Infinity II liquid chromatography system. The peptides were 
separated using a linear gradient of 3% (v/v) solvent B (acetonitrile + 0.1% trifluoroacetic 
acid) in solvent A (water + 0.1% trifluoroacetic acid). The fractions were spotted on a 
MALDI target plate by mixing 1 μl of sample with 1μl of a 25 mg/ml solution of Super-
DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions were 
analyzed by MALDI-TOF MS on a Bruker UltrafleXtreme MALDI-TOF/TOF operating in 
positive ionization, reflector mode.
Primary mouse hepatocytes
Hepatocytes were isolated from C57BL/6 female mice fed the chronic–binge ethanol diet 
(NIAAA model)15. Livers were perfused in situ with 0.5 mM EGTA containing calcium-free 
salt solution and then perfused with a solution containing 0.02% (w/v) collagenase D (Roche 
Applied Science). Livers were then carefully minced and filtered using a 70 μm nylon cell 
strainer. Hepatocytes were centrifuged at 50 x g for 1 min after three times washing. 
Hepatocyte viability was assessed by Trypan Blue (Thermo Fisher Scientific). 1.5 × 105 
hepatocytes were seeded on 12-well plates coated with rat collagen type I in DMEM-F12 
(Thermo Fisher Scientific) with insulin-transferrin-selenium (1% v/v) (Thermo Fisher 
Scientific) and 40 ng/ml dexamethasone (MP Biomedicals) containing 10% (v/v) fetal 
bovine serum (FBS; Gemini Bio-Products) and antibiotics. After 4 hours, the culture was 
washed with DMEM-F12 media and changed to the same complemented media without 
FBS58. Then 16 hours later, hepatocytes were cultured with 0 or 25 mM ethanol and 
stimulated with 0, 200 or 400 nM CylLS” and/or CylLL” in the same culture medium 
without FBS. After 3 hours stimulation, hepatocyte cytotoxicity was assessed using Pierce 
LDH Cytotoxicity Detection Kit (Thermo Fisher Scientific).
Biochemical analysis
Serum levels of ALT were determined using Infinity ALT kit (Thermo Scientific). Hepatic 
triglyceride levels were measured using Triglyceride Liquid Reagents kit (Pointe Scientific). 
Levels of serum LPS and fecal albumin were determined by ELISA kits (Lifeome Biolabs 
and Bethyl Labs, respectively). Serum levels of ethanol were measured using Ethanol Assay 
kit (BioVision).
Staining procedures
Formalin-fixed tissue samples were embedded in paraffin and stained with hematoxylin-
eosin. To determine lipid accumulation, liver sections were embedded in OCT compound. 8 
μm frozen sections were then cut and stained with Oil Red O (Sigma-Aldrich). 
Representative pictures from each group of mice were shown in each figure. The terminal 
deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL) assay was 
performed using an in situ cell death detection kit (Sigma-Aldrich). We randomly selected 
five high-power fields for counting TUNEL-positive cells and normalized numbers to total 
cells.
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Data availability
Raw 16S sequence reads can be found in the NCBI SRA associated with Bioproject 
PRJNA525701. Bacteriophage raw sequence reads and annotated genomes are available at 
NCBI under the following consecutive BioSample IDs (SAMN11089809 – 
SAMN11089827). Genome sequence data of E. faecalis strains isolated in this study were 
registered at ENA under Study PRJEB25007.
Code availability
The PERL script for making the genetic maps of bacteriophage genomes can be found at 
https://github.com/JCVenterInstitute/LinearDisplay.
Statistical analysis
Results are expressed as mean ± s.e.m. (except when stated otherwise). Univariate and 
multivariate Cox regression analysis was used to detect associations of cytolysin with overall 
mortality. The multivariate model was adjusted for geographic origin of the patients; 
antibiotic treatment; platelet count; and creatinine, bilirubin and INR as components of the 
MELD score. Univariate logistic regression analysis of laboratory and clinical parameters 
associated with the detection of cytolysin and E. faecalis was performed. Univariate linear 
regression analysis of laboratory and clinical parameters associated with the log-transformed 
total amount of fecal E. faecalis measured with qPCR was performed. To associate log-
transformed total E. faecalis and E. faecalis positivity with mortality, univariate Cox 
regression was used. P values from Univariate and Multivariate Cox regression, Univariate 
logistic regression and Univariate linear regression were determined by Wald test. 
Multicollinearity was examined using the variance inflation factor (VIF). Kaplan-Meier 
curves were used to compare survival between cytolysin-positive and cytolysin-negative 
alcoholic hepatitis patients. Fecal E. faecalis, bacterial diversity and richness from controls 
and patients were compared using Kruskal-Wallis test with Dunn’s post-hoc test. Region/
center specific clinical characteristics of alcoholic hepatitis patients were compared with 
Kruskal-Wallis test for continuous and Fisher’s exact test for categorical variables. Fecal E. 
faecalis in alcoholic hepatitis patients with or without cytolysin, and with or without 
cirrhosis, were compared with Mann-Whitney-Wilcoxon rank-sum test. Fecal E. faecalis in 
alcoholic hepatitis patients from different region/centers were compared with Kruskal-Wallis 
test. Percentage of subjects with fecal samples positive for E. faecalis and cytolysin was 
compared using Fisher’s exact test, followed by FDR procedures for multiple group 
comparisons. Jaccard dissimilarity matrices were used for principal coordinate analysis 
(PCoA) and P values were determined by permutational multivariate analysis of variance 
(PERMANOVA) followed by FDR procedures to correct for multiple comparisons.
For mouse and cell culture studies, significance of multiple groups was evaluated using one-
way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc test. Fisher’s exact 
test was used in the analysis of liver E. faecalis and cytolysin with FDR correction for 
multiple comparisons. Kaplan-Meier curves were used to compare survival between 
experimental mouse groups. PCoA based on Jaccard dissimilarity matrices was performed 
between experimental mouse groups and the P values were determined by PERMANOVA 
followed by FDR procedures to correct for multiple comparisons.
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Exact P values for all comparisons, together with group size for each group, were listed in 
Supplementary Table 10. Statistical analyses were performed using R statistical software, R 
version 3.5.1, 2018 the R Foundation for Statistical Computing and GraphPad Prism v6.01. 
A P < 0.05 was considered to be statistically significant (adjusted for multiple comparison 
when performing multiple tests).
Extended Data
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Extended Data Figure 1. Intestinal dysbiosis in patients with alcoholic hepatitis.
(a) 16S rRNA sequencing of fecal samples from controls (n=14), patients with alcohol use 
disorder (AUD; n=43), or alcoholic hepatitis (n=75). The graph demonstrates the relative 
abundance of sequence reads in each genus. (b) Bacterial diversity (Shannon-Index and 
Simpson-Index) and richness (Chao-Richness) was calculated in controls (n=14), patients 
with AUD (n=43), or alcoholic hepatitis (n=75). (c) E. faecalis in fecal samples from 
controls (n=25), patients with AUD (n=38), or alcoholic hepatitis (n=82), assessed by qPCR. 
(d) Percentage of fecal samples positive for E. faecalis in controls (n=25), patients with 
AUD (n=38), or alcoholic hepatitis (n=82), assessed by qPCR. E. faecalis was detected in 
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feces from 80% of patients with alcoholic hepatitis vs 36% of controls (P<0.001). There was 
also a significant difference between patients with alcohol use disorder and alcoholic 
hepatitis (P<0.01). (e) ROC curves and AUC for the comparison of 90-day mortality and 
cytolysin positivity (red; n=57), MELD score (blue; n=56), ABIC score (yellow; n=57), and 
DF (green; n=42) in patients with alcoholic hepatitis. (f) E. faecalis in fecal samples from 
patients with alcoholic hepatitis whose fecal samples were cytolysin positive (n=25) or 
cytolysin negative (n=54), assessed by qPCR (P=0.8174). (g) 16S rRNA sequencing of fecal 
samples from patients with alcoholic hepatitis from different centers (France n=9; Mexico 
n=6; Spain n=5; UK n=11; USA East n=16; USA Midwest n=12; USA West n=16). 
Principal coordinate analysis (PCoA) based on Jaccard dissimilarity matrices was used to 
show ß-diversity among groups, at the genus level. Composition of fecal microbiota was 
significantly different (P<0.01). (h) Percentage of fecal samples positive for cylLL and cylLS 
DNA sequences (cytolysin-positive), in patients with alcoholic hepatitis from different 
centers (France n=16; Mexico n=6; Spain n=6; UK n=10; USA East n=16; USA Midwest 
n=13; USA West n=15), assessed by qPCR (P=0.6094). (i) E. faecalis in fecal samples from 
patients with alcoholic hepatitis from different centers, assessed by qPCR (P=0.5648). (j) 
Percentage of fecal samples positive for E. faecalis in patients with alcoholic hepatitis from 
different centers (France n=16; Mexico n=6; Spain n=6; UK n=10; USA East n=16; USA 
Midwest n=13; USA West n=15), assessed by qPCR (P=0.0529). (k) Percentage of subjects 
with fecal samples positive for cylLL and cylLS DNA sequences (cytolysin positive), in 
patients with alcoholic hepatitis and cirrhosis (n=30), or without cirrhosis (n=18), assessed 
by qPCR (P=0.3431). (l) E. faecalis in fecal samples from patients with alcoholic hepatitis 
and cirrhosis (n=30), or without cirrhosis (n=18), assessed by qPCR (P=0.5736). (m) 
Percentage of fecal samples positive for E. faecalis in alcoholic hepatitis patients with 
cirrhosis (n=30), or without cirrhosis (n=18), assessed by qPCR (P=0.2878). Results are 
expressed as as mean ± s.e.m (c, f, i, l). For the Box and Whisker plots in (b), the box 
extends from 25th to 75th percentiles, with the center line representing the median; for all 
three groups, the lower whiskers show the minimum values; for the “Controls” group 
(black), the higher whisker shows the maximum value; for the other two groups, the higher 
whiskers represent the 75th percentile plus 1.5 times inter-quartile distance (the distance 
between the 25th and 75th percentiles), all values greater than this are plotted as individual 
dots. P values are determined by Kruskal-Wallis test (i) with Dunn’s post-hoc test (b,c), two-
sided Fisher’s exact test (h, j, k, m) followed by false discovery rate (FDR) procedures (d), 
two-sided Mann-Whitney-Wilcoxon rank-sum test (f, l), or permutational multivariate 
analysis of variance (PERMANOVA) (g). The exact group size (n) and P values for each 
comparison are listed in Supplementary Table 10. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001.
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Extended Data Figure 2. Cytolytic E. faecalis causes progression of ethanol-induced liver disease 
in mice.
(a–n) C57BL/6 mice were fed oral isocaloric (control) or chronic–binge ethanol diets and 
gavaged with vehicle (PBS), a cytolytic E. faecalis strain (FA2-2(pAM714)) (E. faecalis) 
(5x108 colony forming units (CFUs)), or a non-cytolytic E. faecalis strain 
(FA2-2(pAM771))5 (E. faecalis Δcytolysin) (5x108 CFUs) every third day. (a) Serum levels 
of ALT. (b) Hepatic triglyceride content. (c) Representative oil red O-stained liver sections. 
(d–f) Hepatic levels of mRNAs. (g) Kaplan-Meier curve of survival of mice on chronic–
binge ethanol diets (day 0, start of ethanol feeding). Mice gavaged with PBS all survived and 
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were not included in figure. A higher proportion of mice (n=15) gavaged with non-cytolytic 
E. faecalis survived than mice (n=25) gavaged with cytolytic E. faecalis. (h) Proportions of 
mice positive for cytolysin in liver, measured by qPCR for cylLS (the gene encoding 
cytolysin subunit CylLS”). (i) Proportions of mice positive for E. faecalis in liver, measured 
by qPCR. About 80% of mice colonized with cytolytic E. faecalis, as well as non-cytolytic 
E. faecalis, were positive for E. faecalis in their livers. (j) Liver CFUs of Enterococcus in 
mice on a chronic–binge ethanol diet. (k) Paracellular intestinal permeability was evaluated 
by measuring fecal albumin content and serum levels of lipopolysaccharide (LPS) by 
ELISAs. (l) Fecal samples were collected and 16S rRNA genes were sequenced. Principal 
coordinate analysis based on Jaccard dissimilarity matrices showed no significant 
differences among mice gavaged with PBS, cytolytic or non-cytolytic E. faecalis following 
the diets. Compared to control-diet fed mice, mice fed with ethanol diet had significant 
different fecal microbiomes after gavaging E. faecalis (P<0.05). (m and n) Serum levels of 
ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among 
these mice after ethanol feeding. (o) Mice were gavaged with cytolytic or non-cytolyti E. 
faecalis strains (carrying erythromycin resistance gene; 5x108 CFUs) at time 0, and feces 
was collected at 0, 8, 24, 48, and 72 hrs. Fecal CFUs of Enterococcus were determined by 
culturing fecal samples on BBL Enterococcosel Broth agar plate with 50 μg/ml 
erythromycin. At time 0 and 72, 5/5 and 4/5 mice, respectively, had no detectable 
erythromycin-resistant Enterococcus in feces. These points are not shown on the graph, but 
have been included in the calculation of mean ± s.e.m. Scale bar=100 μm. Results are 
expressed as mean ± s.e.m (a, b, d–f, j, k, m–o). P values among groups of mice fed with 
control diet or ethanol diet are determined by One-way ANOVA with Tukey´s post-hoc test 
(a, b, d–f, j, k, m, n), two-sided Log-rank (Mantel-Cox) test (g), two-sided Fisher’s exact test 
followed by FDR procedures (h and i), or PERMANOVA followed by FDR procedures (l). 
All results were generated from at least three independent replicates. The exact group size 
(n) and P values for each comparison are listed in Supplementary Table 10. P values between 
control-diet fed mice and ethanol-diet fed mice are determined by Two-way ANOVA (k). 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Extended Data Figure 3. Transplantation of cytolysin-positive feces increases ethanol-induced 
liver disease in gnotobiotic mice.
(a–f, h, i) C57BL/6 germ-free mice were colonized with feces from two different cytolysin-
positive and two different cytolysin-negative patients with alcoholic hepatitis, and then fed 
isocaloric (control) or chronic–binge ethanol diets. (a) Percentage of terminal 
deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL) positive hepatic 
cells. (b) Representative oil red O-stained liver sections. (c and d) Hepatic levels of mRNAs 
encoding the inflammatory cytokine Cxcl2, and Acta2 (marker of activated hepatic stellate 
cells). (e) Kaplan-Meier curve of survival of mice on chronic–binge ethanol diets (day 0, 
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start of ethanol feeding) gavaged with feces from cytolysin-positive (n=48 mice) or 
cytolysin-negative (n=32 mice) patients with alcoholic hepatitis. (f) Fecal samples were 
collected and 16S rRNA genes were sequenced. The graph shows principal coordinate 
analysis of fecal microbiomes. No significant difference was observed between mice 
colonized with feces from cytolysin positive or negative alcoholic hepatitis donors following 
the control diet. Mice transplanted with feces from cytolysin-positive alcoholic hepatitis 
patient #2 showed a significantly different microbiota than the other mouse groups following 
ethanol administration (P<0.01). (g) Percentage of cytolysin-positive E. faecalis in 4 patients 
with alcoholic hepatitis. Stool samples from the four patients were placed on plates with 
selective medium and Enterococcus colonies were identified by the production of dark 
brown or black color generated by hydrolysis of esculin to esculetin that reacts with ferric 
ammonium citrate. Enterococcus colonies were confirmed to be E. faecalis by qPCR. 
Cytolysin status of each E. faecalis colony was determined by qPCR. (h) Serum levels of 
ethanol were comparable among colonized mice after ethanol feeding. (i) Hepatic levels of 
Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice on control or 
ethanol diets. Scale bar=100 μm. Results are expressed as mean ± s.e.m (a, c, d, h, i). P 
values are determined by One-way ANOVA with Tukey´s post-hoc test (a, c, d, h, i), two-
sided Log-rank (Mantel-Cox) test (e), or PERMANOVA followed by FDR procedures (f). 
All results were generated from at least three independent replicates. The exact group size 
(n) and P values for each comparison are listed in Supplementary Table 10. *P<0.05, 
**P<0.01, ***P<0.001.
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Extended Data Figure 4. Isolation and amplification of bacteriophages against cytolytic E. 
faecalis isolated from mice.
(a) BHI agar plate showing bacteriophage plaque morphology. Bacteriophage cocktail (100 
μl, 102–103 PFUs) was mixed with overnight grown E. faecalis culture (100 μl) and then 
added to BHI broth top agar (0.5% agar) and poured over a BHI plate (1.5% agar). After 
overnight growth at 37°C, images were captured on an Epson Perfection 4990 Photo 
scanner. (b) Simplified illustration of different bacteriophage morphology. Siphophages have 
long, flexible, noncontractile tails (left), myophages have contractile tails (middle), and 
podophages have short, noncontractile tails (right). (c) Transmission electron microscopy 
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revealed that bacteriophages isolated were all podophages (Efmus1, Efmus2, Efmus3 and 
Efmus4). Phages specific to E. faecalis strain isolated from mouse feces were named as 
Efmus with a number (Ef for E. faecalis, mus for mouse, digit for isolation order). (d) 
Genetic map of phage genomes. The linear maps are based on nucleotide sequences of the 
phage genomes and predicted open reading frames. The name and length (bp) of each 
genome are indicated to the left of each phage map. Protein-coding sequences are colored 
based on functional role categories (see box). Scale bar=50 nm. All results were generated 
from at least three independent replicates.
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Extended Data Figure 5. Phages reduce translocation of cytolysin to the liver and reduce 
ethanol-induced liver disease in Atp4aSl/Sl mice.
(a–k) Wild-type (WT) and their Atp4aSl/Sl littermates were fed oral isocaloric (control) or 
chronic–binge ethanol diets and gavaged with vehicle (PBS), control phages against C. 
crescentus (1010 plaque forming units (PFUs)), or a cocktail of 4 different phages targeting 
cytolytic E. faecalis (1010 PFUs) 1 day before ethanol binge. (a) Serum levels of ALT. (b) 
Hepatic triglyceride content. (c) Representative oil red O-stained liver sections. (d–f) 
Hepatic levels of mRNAs. (g) Proportions of mice positive for cytolysin in liver, measured 
by qPCR for cylLS. (h) Fecal colony forming units (CFUs) of Enterococcus. (i) Fecal 
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samples were collected and 16S rRNA genes were sequenced. Principal coordinate analysis 
based on Jaccard dissimilarity matrices found no significant difference in fecal microbiota 
among mice given PBS, control phage, or phages targeting cytolytic E. faecalis in each 
group. (j and k) Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did 
not differ significantly among colonized mice after ethanol feeding. Scale bar=100 μm. 
Results are expressed as mean ± s.e.m (a, b, d–f, h, j, k). P values are determined by Two-
way ANOVA with Tukey´s post-hoc test (a, b, d–f, h, j, k), two-sided Fisher’s exact test 
followed by FDR procedures (g), or PERMANOVA followed by FDR procedures (i). All 
results were generated from at least three independent replicates. The exact group size (n) 
and P values for each comparison are listed in Supplementary Table 10. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001.
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Extended Data Figure 6. Isolation and amplification of bacteriophages against cytolytic E. 
faecalis isolated from patients with alcoholic hepatitis.
(a) BHI agar plates showing bacteriophage plaque morphology. (b) Transmission electron 
microscopy graphs of myophages Ef2.1 and Ef2.3, stained with phosphotungstic acid 
showing contracted tails. (c) Genetic map of phage genomes. The linear maps are based on 
nucleotide sequences of the phage genomes and predicted open reading frames. The name 
and length (bp) of each genome are indicated to the left of each phage map. Protein-coding 
sequences are colored based on functional role categories (see box). Sequences encoding 
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tRNA genes are indicated by a cloverleaf structure. Scale bar=50 nm. All results were 
generated from at least three independent replicates.
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Extended Data Figure 7. Phages that target cytolytic E. faecalis reduce ethanol-induced liver 
disease in gnotobiotic mice.
(a–h) C57BL/6 germ-free mice were colonized with feces from two different cytolysin-
positive patients with alcoholic hepatitis (feces from 1 patient is used in Figure 2). The mice 
were then fed oral isocaloric (control) or chronic–binge ethanol diets, and gavaged with 
control phages against C. crescentus (1010 plaque forming units (PFUs)), or a cocktail of 3 
or 4 different phages targeting cytolytic E. faecalis (1010 PFUs) 1 day before an ethanol 
binge. (a) Percentage of TUNEL-positive hepatic cells. (b) Representative oil red O-stained 
liver sections. (c and d) Hepatic levels of mRNAs encoding the inflammatory cytokine 
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Cxcl2, and Acta2 (marker of activated hepatic stellate cells). (e) Fecal colony forming units 
(CFUs) of Enterococcus. (f) Fecal samples were collected and 16S rRNA genes were 
sequenced. Principal coordinate analysis based on Jaccard dissimilarity matrices shows no 
significant differences in fecal microbiota of mice gavaged with control phage and phages 
targeting cytolytic E. faecalis in each group. (g and h) Serum levels of ethanol and hepatic 
levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized mice after 
ethanol feeding. Scale bar=100 μm. Results are expressed as mean ± s.e.m (a, c–e, g, h). P 
values are determined by Two-way ANOVA with Tukey´s post-hoc test (a, c–e, g, h), or 
PERMANOVA followed by FDR procedures (f). All results were generated from at least 
three independent replicates. The exact group size (n) and P values for each comparison are 
listed in Supplementary Table 10. *P<0.05, ***P<0.001.
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Extended Data Figure 8. Isolation and amplification of bacteriophages against non-cytolytic E. 
faecalis isolated from patients with alcoholic hepatitis.
(a) BHI agar plates showing bacteriophage plaque morphology. (b) Genetic map of phage 
genomes. The linear maps are based on nucleotide sequences of the phage genomes and 
predicted open reading frames. The name and length (bp) of each genome are indicated to 
the left of each phage map. Protein-coding sequences are colored based on functional role 
categories (see box). Sequences encoding tRNA genes are indicated by a cloverleaf 
structure. (c) Phylogenetic tree of Enterococcus bacteriophages. A whole-genome average 
nucleotide distance tree was constructed for 73 available Enterococcus phage genomes, 54 
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from GenBank (black letters), 19 from this study (4 phages against cytolysin-positive E. 
faecalis isolated from mice in blue letters, 7 phages against cytolysin-positive E. faecalis 
isolated from alcoholic hepatitis patients in pink letters, and 8 phages against cytolysin-
negative E. faecalis isolated from alcoholic hepatitis patients in green letters) with Mash43 
using a sketch size of s=5000 and k-mer size of k=12 and GGRaSP59 (see Methods). 
Colored branches denote specific phage genera: Sap6virus, P68virus and Spounavirinae. The 
scale bar represents percent average nucleotide divergence. All results were generated from 
at least three independent replicates.
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Extended Data Figure 9. Phages that target non-cytolytic E. faecalis do not reduce ethanol-
induced liver disease in gnotobiotic mice.
(a–h) C57BL/6 germfree mice were colonized with feces from two different cytolysin-
negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral 
isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages against 
C. crescentus (1010 plaque forming units (PFUs)), or a cocktail of 4 different phages 
targeting non-cytolytic E. faecalis (1010 PFUs) 1 day before an ethanol binge. (a) Percentage 
of TUNEL-positive hepatic cells. (b) Representative oil red O-stained liver sections. (c and 
d) Hepatic levels of mRNAs encoding the inflammatory cytokine Cxcl2, and Acta2 (marker 
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of activated hepatic stellate cells). (e) Proportions of mice positive for cytolysin in liver, 
measured by qPCR for cylLS. (f) Fecal samples were collected and 16S rRNA genes were 
sequenced. Principal coordinate analysis based on Jaccard dissimilarity matrices found no 
significant difference in fecal microbiota among mice gavaged with control phages and 
phages targeting cytolytic E. faecalis in each group. (g and h) Serum levels of ethanol and 
hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ significantly among colonized 
mice after ethanol feeding. Scale bar=100 μm. Results are expressed as mean ± s.e.m (a, c, 
d, g, h). P values are determined by Two-way ANOVA with Tukey´s post-hoc test (a, c, d, g, 
h), two-sided Fisher’s exact test followed by FDR procedures (e), or PERMANOVA 
followed by FDR procedures (f). All results were generated from at least three independent 
replicates. The exact group size (n) and P values for each comparison are listed in 
Supplementary Table 10.
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Abbreviations
ABIC Age, serum bilirubin, INR, and serum creatinine score
Acta2 smooth muscle actin alpha 2
Adh1 alcohol dehydrogenase 1
AH alcoholic hepatitis
ALT alanine amino-transferase
ANOVA analysis of variance
AUC area under the curve
AUD alcohol use disorder
BHI broth, brain heart infusion broth
C. crescentus Caulobacter crescentus
CFUs colony forming units
CI confidence interval
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Col1a1 collagen, type I, alpha 1
Cxcl chemokine (C-X-C motif) ligand
Cyp2e1 cytochrome P450 family 2 subfamily E polypeptide 1
DF discriminant function
E. coli Escherichia coli
E. faecalis Enterococcus faecalis
FDR false discovery rate
FIB-4 fibrosis-4 index
HR hazard ratio
Il1b interleukin 1 beta
INR international normalized ratio
LB medium Luria-Bertani medium
LDH lactate dehydrogenase
LPS lipopolysaccharide
MELD model for end-stage liver disease
MELDNa sodium MELD
MOI multiplicity of infection
PBS phosphate-buffered saline
PCoA principal coordinate analysis
PERMANOVA permutational multivariate analysis of variance
PFUs plaque forming units
qPCR quantitative PCR
ROC receiver operating characteristic
rRNA ribosomal RNA
RT room temperature
SNP single nucleotide polymorphism
TUNEL terminal deoxynucleotide transferase-mediated dUTP nick-
end labeling
VIF variance inflation factor
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Figure 1. E. faecalis cytolysin associates with mortality in patients with alcoholic hepatitis.
(a) 16S rRNA sequencing of fecal samples from controls (n=14), patients with alcohol use 
disorder (AUD; n=43), or alcoholic hepatitis (n=75). Principal coordinate analysis (PCoA) 
based on Jaccard dissimilarity matrices was used to show ß-diversity among groups, at the 
genus level. Composition of fecal microbiota was significantly different between each group 
(P<0.01). (b) Percentage of subjects with fecal samples positive for cylLL and cylLS DNA 
sequences (cytolysin-positive), in controls (n=25), patients with AUD (n=38), or alcoholic 
hepatitis (n=82), assessed by qPCR. Statistically significant differences were detected 
between controls and alcoholic hepatitis patients (P<0.01), and between patients with 
alcohol use disorder and alcoholic hepatitis patients (P<0.001). (c) Kaplan-Meier curve of 
survival of patients with alcoholic hepatitis whose fecal samples were cytolysin-positive 
(n=25) or cytolysin-negative (n=54) (P<0.0001). (d) Core genome single nucleotide 
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polymorphism (SNP) tree of E. faecalis strains isolated from patients with alcoholic hepatitis 
(n=93 from 24 patients), showing phylogenetic diversity of cytolysin-positive (red) E. 
faecalis. Genomically identical isolates from the same patient were combined and are shown 
as one single dot. Scale bar represents the nucleotide substitutions per SNP site. P values are 
determined by permutational multivariate analysis of variance (PERMANOVA) followed by 
false discovery rate (FDR) procedures (a), two-sided Fisher’s exact test followed by FDR 
procedures (b), or two-sided Log-rank (Mantel-Cox) test (c). The exact group size (n) and P 
values for each comparison are listed in Supplementary Table 10.
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Figure 2. Transplantation of feces from cytolysin-positive patients with alcoholic hepatitis 
exacerbates ethanol-induced liver disease in gnotobiotic mice.
(a–g) C57BL/6 germfree mice were colonized with feces from two different cytolysin-
positive and two different cytolysin-negative patients with alcoholic hepatitis and subjected 
to the chronic–binge feeding model. (a) Serum levels of ALT. (b) Hepatic triglyceride 
content. (c) Representative H&E-stained liver sections. (d–f) Hepatic levels of mRNAs 
encoding Il1b, Cxcl1, and Col1a1. (g) Proportions of mice positive for cytolysin in liver, 
measured by qPCR for cylLS. (h) LDH assay to measure cytotoxicity of hepatocytes isolated 
from mice fed oral isocaloric (control) diet (5 groups, left) or chronic–binge ethanol diet (5 
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groups, right) and incubated with vehicle, CylLS”, CylLL”, or both cytolysin subunits, at 
indicated concentrations, without (–) or with (+) ethanol (25mM) for 3 hours. Survival of 
hepatocytes was determined in 3 independent experiments. Scale bar=100 μm. Results are 
expressed as mean ± s.e.m (a, b, d–f, h). P values are determined by One-way ANOVA with 
Tukey´s post-hoc test (a, b, d–f), two-sided Fisher’s exact test followed by FDR procedures 
(g), or Two-way ANOVA with Tukey´s post-hoc test (h). All results were generated from at 
least three independent replicates. The exact group size (n) and P values for each comparison 
are listed inSupplementary Table 10. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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Figure 3. Phage therapy against cytolytic E. faecalis abolishes ethanol-induced liver disease in 
gnotobiotic mice.
(a) Transmission electron microscopy revealed that bacteriophages isolated were either 
siphophages (Ef5.1, Ef5.2, Ef5.3, Ef5.4 and Ef2.2) or myophages (Ef2.1 and Ef2.3). Scale 
bar=50 nm. (b–h) C57BL/6 germfree mice were colonized with feces from two different 
cytolysin-positive patients with alcoholic hepatitis (feces from 1 patient also used in Figure 
2) and subjected to chronic–binge feeding model, gavaged with control phages against C. 
crescentus (1010 PFUs), or a cocktail of 3 or 4 different phages targeting cytolytic E. faecalis 
(1010 PFUs) 1 day before an ethanol binge. (b) Serum levels of ALT. (c) Hepatic triglyceride 
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content. (d) Representative H&E-stained liver sections. Scale bar=100 μm. (e–g) Hepatic 
levels of mRNAs encoding Il1b, Cxcl1 and Col1a1. (h) Proportions of mice positive for 
cytolysin in liver, measured by qPCR for cylLS. Results are expressed as mean ± s.e.m (b, c, 
e–g). P values are determined by Two-way ANOVA with Tukey´s post-hoc test (b, c, e–g) or 
two-sided Fisher’s exact test followed by FDR procedures (h). All results are generated from 
at least three independent replicates. The exact group size (n) and P values for each 
comparison are listed in Supplementary Table 10. *P<0.05, **P<0.01, *** P<0.001.
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Figure 4. Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced liver disease 
in gnotobiotic mice.
(a) Transmission electron microscopy revealed that bacteriophages isolated were either 
podophages (Ef6.2, Ef6.3, Ef7.2, Ef7.3 and Ef7.4) or siphophages (Ef6.1, Ef6.4 and Ef7.1). 
Scale bar=50 nm. (b–h) C57BL/6 germfree mice were colonized with feces from two 
different cytolysin-negative patients with alcoholic hepatitis and subjected to chronic–binge 
feeding model, gavaged with control phages against C. crescentus (1010 PFUs), or a cocktail 
of 4 different phages targeting non-cytolytic E. faecalis (1010 PFUs) 1 day before an ethanol 
binge. (b) Serum levels of ALT. (c) Hepatic triglyceride content. (d) Representative H&E-
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stained liver sections. Scale bar=100 μm. (e–g) Hepatic levels of mRNAs encoding Il1b, 
Cxcl1, and Col1a1. (h) Fecal colony forming units (CFUs) of Enterococcus. Results are 
expressed as mean ± s.e.m (b, c, e–h). P values are determined by Two-way ANOVA with 
Tukey´s post-hoc test (b, c, e–h). All results were generated from at least three independent 
replicates. The exact group size (n) and P values for each comparison are listed in 
Supplementary Table 10. *P<0.05.
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